SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune… Read more
SAB Biotherapeutics Inc (SABS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.079x
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has a cash flow conversion efficiency ratio of -0.079x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.05 Million) by net assets ($165.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SAB Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how SAB Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SAB Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SAB Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TBS Energi Utama Tbk PT
JK:TOBA
|
0.003x |
|
Helius Minerals Limited
V:HHH
|
N/A |
|
Cystech Electronics Corp
TWO:6651
|
0.066x |
|
Unimot S.A
WAR:UNT
|
-0.064x |
|
EREUF
PINK:EREUF
|
0.006x |
|
HI Mobility Berhad
KLSE:5335
|
0.039x |
|
Axactor SE
OL:ACR
|
-0.040x |
|
5QQ
F:5QQ
|
-0.048x |
Annual Cash Flow Conversion Efficiency for SAB Biotherapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of SAB Biotherapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $25.97 Million | $-34.29 Million | -1.320x | -201.21% |
| 2023-12-31 | $57.30 Million | $-25.12 Million | -0.438x | +41.96% |
| 2022-12-31 | $31.06 Million | $-23.46 Million | -0.755x | -1565.54% |
| 2021-12-31 | $38.55 Million | $1.99 Million | 0.052x | -79.90% |
| 2020-12-31 | $39.01 Million | $10.00 Million | 0.256x | -93.58% |
| 2019-12-31 | $-2.31 Million | $-9.21 Million | 3.997x | -- |